Pages that link to "Q53790905"
Jump to navigation
Jump to search
The following pages link to Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies. (Q53790905):
Displaying 25 items.
- An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins (Q26823562) (← links)
- Biosimilar insulins: guidance for data interpretation by clinicians and users (Q26992066) (← links)
- Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine (Q33732607) (← links)
- Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus (Q37561045) (← links)
- Insulin analogues in type 1 diabetes mellitus: getting better all the time (Q38692387) (← links)
- Modeling Pharmacokinetic Profiles of Insulin Regimens to Enhance Understanding of Subcutaneous Insulin Regimens (Q38844536) (← links)
- Comparison of morning basal 1 bolus insulin therapy (insulin glulisine insulin glargine 300 U/mL vs insulin lispro insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study. (Q38858785) (← links)
- Euglycaemic glucose clamp: what it can and cannot do, and how to do it. (Q38871135) (← links)
- Introduction of biosimilar insulins in Europe (Q39368850) (← links)
- Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine (Q40125071) (← links)
- Insulin's Role in Diabetes Management: After 90 Years, Still Considered the Essential "Black Dress". (Q43158349) (← links)
- Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. (Q46199321) (← links)
- Switching basal insulins in type 2 diabetes: practical recommendations for health care providers (Q48088343) (← links)
- LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels (Q49899858) (← links)
- How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins? (Q50131255) (← links)
- Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review. (Q52580579) (← links)
- Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials. (Q52591845) (← links)
- Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c. (Q52603694) (← links)
- Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union. (Q54159731) (← links)
- A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus. (Q55162068) (← links)
- A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study (Q58763121) (← links)
- Lilly Insulin Glargine Versus Lantus in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5) (Q61807531) (← links)
- Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study (Q88063137) (← links)
- Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation (Q88946729) (← links)
- Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability (Q94219595) (← links)